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1091-207 Primary and Secondary Prevention Implantable 
Cardioverter Defibrillator Patients Have Similar 
Proportions of Ventricular Tachyarrhythmia Detections 
and Equivalent Risk for Spurious Therapies: Results 
From PainFREE Rx II
Michael O. Sweeney, Mark S. Wathen, Ismaile Abdalla, Paul J. DeGroot, Mary F. 
Otterness, Alice J. Stark, Brigham and Women's Hospital, Boston, MA, Vanderbilt 
University Medical Center, Nashville, TN
Background: ICDs reduce mortality in primary (Prim) and secondary (Second) preven-
tion pts. However, "overtreatment" in Prim remains a concern, potentially at the cost of
spurious therapies for inappropriate ventricular detections due to SVT. We compared
appropriate and inappropriate ventricular detections in 584 pts (Prim = 202, 35%; Sec-
ond = 382, 65%) in PainFREE Rx II, a prospective randomized study of antitachycardia
pacing (ATP) or shocks for fast VT (FVT).
Methods: All ICDs were identically programmed at implant with 3 zones (VT < 188 bpm;
FVT = 188-250 bpm; VF > 250 bpm) but with either ATP or shock for FVT. An expert
panel adjudicated all detected episodes that had stored electrograms. GEE methods
were used to account for multiple episodes/pt and are reflected in percentages and p-val-
ues.
Results: Prim pts were significantly older, had lower EF and more CAD. Gender, b-block-
ers, antiarrhythmic drugs, and length of follow-up were similar between groups. During
follow-up of 11 ± 3 months, 1670 ventricular episodes were detected as: 738 VT, 391
FVT, 123 VF, and 418 SVT. The distribution of VT, FVT, and VF was similar between Prim
vs Second (VT: 99/276 [44%] vs 639/976 [46%], p=0.77; FVT: 138/276 [41%] vs 253/976
[39%], p=0.71; VF: 39/276 [15%] vs 84/976 [14%], p=0.86). Proportion of pts with >1
appropriate episode was similar in Prim vs Second (21% vs 27%, p=0.13). But among
pts with appropriate episodes, the median number of episodes per pt was significantly
lower for Prim than for Second (1 vs 3, p=.05). The proportion of pts with >1 inappropri-
ate episode was similar in Prim vs Second (16% vs 15%, p=0.81), and the proportion of
inappropriate episodes was greater in Prim but the difference was not significant (Prim,
121/397 [42%] vs Second, 297/1273 [34%], p=.21).
Conclusions: Similar proportions of Prim and Second pts have appropriate detections
for potentially life-threatening VT, FVT and VF but with less frequency in Prim. Inappropri-
ate detections account for more than one-third of all ventricular episodes in both groups.
Prim pts do not appear to be "overtreated" compared to Second pts and are at equivalent
risk for spurious therapies.
1091-208 Syncope in Implantable Cardioverter Defibrillator 
Patients: Predictors and Outcomes
Dalia Giedrimiene, Danette Guertin, Jeffrey Kluger, Hartford Hospital, Hartford, CT
Background: The ability of ICD to terminate ventricular tachyarrhythmias and to reduce
the rate of sudden death is well established. However, syncope may still occur and
impact quality of life and survival. The purpose of this study was to identify predictors of
syncope development in patients with ICD therapy using clinical and electrophysiological
characteristics.
Methods: We retrospectively reviewed a prospectively collected ICD database of 309 pts
with primary ICD implants at our institution between 1999 and 2002. 139 pts developed
ICD therapy during a mean follow-up period of 21.7±11.6 months. There were 108 males
and 31 females (av. age 65.2±11.8) with the following presenting arrhythmias: 56 (40.3%)
- sustained monomorphic ventricular tachycardia (MVT); 19 (13.7%) - ventricular fibrilla-
tion (VF), 44 (31.7%) - non-sustained ventricular tachycardia (NSVT); and 20 (14.4%) -
syncope. Groups of pts with syncope during ICD therapy and without syncope were com-
pared for clinical and electrophysiological variables and outcomes.
Results: 
Conclusions: Syncope is not uncommon at the time of ICD device therapy and occurs in
older patients with more depressed EF. Patients with syncope during ICD therapy are
more likely to have syncope at presentation. ICD related proarrhythmia occurs more fre-
quently, and the rate of ICD treated VT is faster in patients with syncope. The total mor-
tality also appears to be greater in ICD patients who experience syncope at the time of
device therapy.
1091-209 Cardiac Resynchronization Therapy Results in a Lower 
Arrhythmia Burden
Philippine Kiès, Sander G. Molhoek, Jeroen J. Bax, Lieselot van Erven, Marianne 
Bootsma, Katja Zeppenfeld, Ernst E. van der Wall, Martin J. Schalij, Leiden University 
Medical Center, Leiden, The Netherlands
Introduction: Patients at high-risk for ventricular tachycardias due to dilated cardiomyop-
athy who are treated with an Implantable Cardioverter Defibrillator (ICD) may progress to
severe heart failure. These patients may become eligible for cardiac resynchronisation
therapy (CRT) by means of biventricular pacing. We hypothesized that CRT can affect
the number of arrhythmic events. The aim of this study was to evaluate whether long-
term CRT influences the number of ventricular tachycardias in patients with dilated cardi-
omyopathy implanted with a CRT-ICD.
Methods: Seventeen ICD patients (13 men, age 60 ±11yrs, 59% ischemic heart dis-
ease) were studied. The NYHA class was 3.2±0.4, with a left ventricular ejection fraction
(LVEF) of 19.5±7 %. Each patient underwent an upgrade to a CRT-ICD device. The num-
ber of ICD therapies was obtained by analyzing the ICD printouts, which were acquired
every 3 months during the year before and the year after upgrading. Clinical data were
obtained during outpatient clinic visits and by chart-review.
Results: At 12-month follow-up after CRT treatment NYHA class improved to 2.2±0.5
(p<0.01) and LVEF improved to 23.5±9% (p<0.01). During the year before implantation of
the ICD-CRT device, 8 of 17 patients (47%) experienced 242 VT episodes. After implan-
tation of the CRT device 3 of 17 patients (18%) experienced 19 VT episodes (p =0.01).
None of the patients experienced an episode of ventricular fibrillation during the evalu-
ated period.
Conclusion: Upgrade to CRT-ICD improves heart failure status and LVEF, and reduces
the number of ventricular arrhythmias.
1091-210 The World Trade Center Attack: Increased Frequency of 
Defibrillator Shocks for Ventricular Arrhythmias in 
Patients Living Remotely From New York City
Omer L. Shedd, Jonathan S. Steinberg, Aysha Arshad, Jane Harvill, Anne Curtis, 
University of Florida, Gainesville, FL
Background: A two-fold increase in the frequency of implantable cardioverter defibrilla-
tor (ICD) shocks for potentially life-threatening ventricular arrhythmias was reported
among patients living in New York City in the month following the attack on the World
Trade Center (WTC) compared to the month before the tragedy. However, whether this
effect also occurred in patients living geologically distant from New York is unknown. We
sought to determine whether the attack on 9/11/01 had an effect on the occurrence of
ventricular arrhythmias among patients with ICDs living in Florida at that time.
Methods:This was an observational study in which the population consisted of 132 con-
secutive ICD patients who presented to the University of Florida and the Veterans Affairs
(VA) Hospital in Gainesville, Florida for routine ICD follow-up around the time of the WTC
attack. The occurrence of ventricular tachyarrhythmias that triggered ICD therapy in the
30 days before and after 9/11/01 constituted our primary end point.
Results: In the 30 days following the WTC attack a total of 14 patients (11%) had ventric-
ular tachyarrhythmias, compared to only 5 patients (3.5%) in the preceding 30 days. This
represents a 3.14-fold increase in risk. Patients with ventricular arrhythmias both before
and after 9/11/01 demonstrated a rate increased of 2.38 events per patient (95%
CI=0.05-0.40 p=0.00042)
Conclusions: The frequency of ventricular arrhythmias requiring ICD treatment
increased by more than 3-fold among patients living in Florida around the time of the
WTC attack. Moreover, patients with ventricular arrhythmias in the 30 days before and
after 9/11/01 experienced at least a doubling of the rate of arrhythmia. These finding sug-
gest that stress related arrhythmogenesis due to the WTC tragedy was not restricted to
the geographical location of the attack. Additionally, the attacks likely caused more signif-
icant levels of morbidity because they affected a larger number of patients than previ-
ously estimated. A major national tragedy may cause a widespread increase risk of
potentially life-threatening ventricular arrhythmias.
1091-211 Heart Rate Dynamics Before the Onset of Ventricular 
Tachyarrhythmias: Results of the Cardioverter 
Defibrillator Registry MARITA
Alexander Schirdewan, Udo Meyerfeldt, Niels Wessel, Hans J. Bondke, Peter Schreiber, 
Rainer Sadowski, Wolfram Kamke, Michael Wiedemann, Franz-Volhard-Hospital, 
Charite, Helios-Klinikum, Humboldt-University, Berlin, Germany
Background: Implantable Cardioverter-Defibrillators (ICDs) are the standard therapy in
patients with ventricular tachyarrhythmia (VTA) and provide a unique opportunity to ana-
lyze beat-to-beat (RR)-interval variability (HRV) before the onset of such life-theatening
event. The aim of this study was to assess the ability of a Multivariate Analysis of RR-
Intervals to predict these VTA (MARITA Trial).
METHODS: One hundred eighty-six patients (153 men, mean age 61.0±10.4) with an
implanted ICD (Biotronik, 9000 RR-intervals capacity) for recurrent VTA provided 257
heart rate recordings before a VTA (94 patients) and 645 series during control conditions:
recordings at follow-up date without VTA. From these time series we analysed 107 VTA
and 422 control recordings which were in sinus rhythm, more than one hour long and had
Variables Syncope n=30 No Syncope n=109 P-value 
Age 65.3±10.8 63.6±12.5 0.463
Gender M/F 23/7 85/24
Lowest EF % 23.1±15.6 30.7±16.8 0.05*
Inducible VT (%) 15 (50%) 77(70.6%) 0.05*
Ischemic Heart Disease 21(70%) 74(67.9%) 0.83
ICD treated VT cycle (ms) 237.5±50.1 309.3±32.55 0.001*
More than 1 shock of ICD 5(16.7%) 29(26.6%) 0.22
ICD proarrhythmia % 5 (16.7%) 7 (6.4%) 0.05*
Syncope at presentation % 18 (60%) 42 (38.5%) 0.042*
Mortality % 11 (36.7%) 19(17.4%) 0.05*
Mortality in less than 6 months 2/11(18.2%) 6/19 (39.6%) 0.42
* p < 0.05
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less than 10 % ventricular ectopy. For HRV analysis standard time- and frequency
parameters as well as nonlinear dynamical measures were calculated. To determine the
time of sympathetic activation we calculated all HRV parameter for successive 5 minutes
intervals up to 90 minutes before the onset of VTA.
Results: The mean RR-interval for VTA was significantly lower than for the controls
(752.4±13.9 vs. 819.1±8.1, p<0.0001), whereas the number of ventricular premature
beats (VPBs) was higher (230.5±19.7 versus 147.7±10.5, p<0.00001). Heart rate and
ventricular ectopy rate significant increase already 90 minutes before VTA onset com-
pared with control conditions suggesting a state of sympathetic excitation. Mean heart
rate and the number of VPBs were statistically significant for all comparisons. The sym-
bolic dynamics parameter POLVAR10 in addition detected a further sympathetic excita-
tion 10 minutes before the onset of VTA, whereas all other parameters failed to detect
these changes.
Stepwise discriminant function analysis gave a classification rate between VTA and con-
trol series of 77.1 % with a positive predictive accuracy of 51.4 % and a negative predic-
tive accuracy of 88.3 %.
CONCLUSIONS: First results of this study suggest, that monitoring of heart rate dynam-
ics in ICD patients can predict VTA events with a positive accuracy for VTA of about 50%.
1091-212 Heart Rate Variability Footprint: New Diagnostic Tool to 
Monitor the Clinical Benefit of Cardiac 
Resynchronization Therapy in Patients With End-Stage 
Heart Failure
Marianne Bootsma, Philippine Kiès, Sander G. Molhoek, Rob de Melker, Lieselot van 
Erven, Ernst E. van der Wall, Martin J. Schalij, Leiden University Medical Center, Leiden, 
The Netherlands
Introduction: Heart rate variability (HRV) is a noninvasive measure of cardiac autonomic
control. Decreased HRV is an independent risk factor in patients with chronic heart-fail-
ure (HF). Cardiac resynchronisation therapy (CRT) improves functional capacity and
reduces morbidity in end-stage HF patients. We hypothesized that changes in symptoms
and functional status in HF patients as a result of CRT are reflected by changes in auto-
nomic output and are displayed by HRV. We studied HRV "footprints" after ICD implanta-
tion and 6 months later obtained via a novel patient diagnostic tool available in the
dedicated biventricular defibrillator (Renewal, Guidant, MN, USA) in patients with class
III-IV heart failure.
Methods: Between July 2001 and May 2002, Renewal ICD's were implanted in
91patients. Twenty-seven patients were excluded from the HRV-study because of atrial
fibrillation and/or atrial pacing. Of the remaining 64 patients footprints of HRV were mea-
sured as percentage of square plot surface (X-axis heart rate, Y-axis RR-variability) on
the third day after implantation and 6 months later. Correlations were made with the Min-
nesota quality-of-life (QOL) score and 6-minute-walking test.
Results: Comparison between the baseline plot and the 6-month plot showed improve-
ment in HRV in 46 patients (71%) and the footprint percentage increased with 22 ±12 %
(min 10 %, max 52% improvement). In 18 patients (28 %) no improvement was seen.
The improvement and deterioration obtained with the patient diagnostic tool correlated
significantly with the improvement or deterioration in QOL score (r=0.681, p<0.5) and 6-
MWT (r=0.581, p=0.004)
Conclusion: A significant correlation was found between HRV changes and changes in
QOL and 6-minute-walking test. The novel patient diagnostic tool allows to obtain HRV
footprints and could be used to monitor heart failure patients treated with resynchronisa-
tion therapy.
1091-223 The Implantable Defibrillator and the Long QT 
Syndrome: An Overview of Current Use and Outcome
Lia Crotti, Carla Spazzolini, Maurizio Landolina, Gaetano M. De Ferrari, Raffaella Bloise, 
Carlo Napolitano, Gerold Monnig, Pedro Brugada, Lauri Toivonen, Stefan H. Hohnloser, 
Silvia G. Priori, Peter J. Schwartz, University of Pavia, Pavia, Italy, IRCCS Policlinico S. 
Matteo, Pavia, Italy
The use of the implantable cardioverter-defibrillator (ICD) in the long QT syndrome
(LQTS) presents specific complexities (young age, stress-induced events, efficacy of
antiadrenergic therapy). The European LQTS-ICD Registry is an ongoing project which
enrolls LQTS pts with an ICD to analyze current criteria for implant and to assess out-
come. While there is a consensus to implant cardiac arrest (CA) survivors, other indica-
tions are controversial. So far, 90 pts (81% females, QTc 514±59 ms, 37% of known
genotype) were enrolled. Before implant 98% were symptomatic, CA had occurred in
50% [60% of these prior to β-blockers (BB) therapy]. However, 43 pts (48%) had only
syncope: 69% of them despite BB and 31% without therapy. During a 2.8±2.5 years
mean follow-up, appropriate shocks occurred in 19% while inappropriate shocks were
received by 7% of the pts. A replacement (13%) or repositioning (10%) had to be per-
formed in 23% of pts while 7% received multiple repetitive discharges, average over 50
shocks/pt. Of the appropriate shocks, 73% occurred in pts with prior CA; conversely, only
9% of the 45 pts with (n=43) or without (n=2) syncope independently of BB had appropri-
ate shocks. Of the pts not on BB therapy prior to implant, 23% remained without therapy.
In conclusion, ICD implant appears useful in pts with a prior CA, but in pts with syncope
only the rate of shocks is low. The Registry reveals potential pitfalls in current manage-
ment of LQTS: many pts receive an ICD just because of syncope or of family history and
are exposed to significant complications, while others are left without anti-arrhythmic pro-
tection after implant. With LQTS pts, the ICD needs to be complemented by effective
antifibrillatory therapy to minimize the risk of shocks, even when appropriate.
1091-224 Long-Term Outcome of Patients With Cardiac 
Sarcoidosis Receiving Implantable Cardioverter 
Defibrillators
Samantapudi Daya, Harikrishna Tandri, Hugh Calkins, The Johns Hopkins University 
School of Medicine, Baltimore, MD
Background: Patients with cardiac sarcoidosis often develop malignant ventricular
arrhythmias necessitating implantable cardioverter-defibrillator (ICD) therapy for second-
ary prevention of sudden death. The long term outcome and the predictors of survival in
these patients are unknown. 
Methods and Results-: The study population included ten patients who were prospec-
tively diagnosed with cardiac sarcoidosis and received ICDs for secondary prevention of
sudden death. Baseline characteristics included demographics, implant indication, left
ventricular ejection fraction, and NYHA functional class. Outcome measures included
death, cardiac transplantation and time to first ICD therapy. The study group included six
male and four female patients with a mean age of 42 ± 9 yrs. Fifty percent were Cauca-
sian and the rest African American. Over a mean follow up of 48±14 months, four deaths
occurred in the study population. The 1-, 2-, and 5-year survival was 100%, 67% and
44% respectively. NYHA functional class III and IV heart failure at the time of ICD implan-
tation predicted poor long-term survival (p=0.01). Age at implant, gender and the left ven-
tricular ejection fraction did not have an impact on survival. Nine (90%) of the ten patients
received appropriate ICD therapy. The mean duration to first ICD therapy was 10 ± 7
months after the implant. There were no inappropriate therapies.
Conclusions- Patients with cardiac sarcoidosis who receive ICDs for secondary preven-
tion of sudden death have a high rate of arrhythmia recurrence requiring ICD interven-
tion. Poor NYHA functional class at the time of device implantation is associated with
worse long-term survival.
1091-225 Atrial Antitachycardia Pacing Efficacy Based on Time 
and Rhythm
Emile G. Daoud, Robert Hoyt, Koonlawee Nademanee, Charles Fuenzalida, Helen 
Reeve, Melissa Simones, Crystal Stone, Mark Schwartz, Riverside Methodist Hospital, 
Columbus, OH, Iowa Heart Center, Des Moines, IA
Background: Atrial antitachycardia pacing (ATP) has been incorporated into implanted
devices in an effort to provide painless therapy for atrial tachycardia, flutter and fibrilla-
tion.Controversy exists as to which atrial tachyarrhythmias (AT) are susceptible to ATP
therapy as well as appropriate calculations of efficacy with respect to time post therapy.
Methods: This study looked at the efficacy of atrial ATP on AT episodes from patients
implanted with an atrial and ventricular defibrillator (PRIZM AVT, Guidant Corp). Epi-
sodes receiving ATP were retrospectively classified as SVT, disorganized SVT (DSVT) or
atrial fibrillation (Afib). Overall atrial ATP efficacy was calculated as well as efficacy within
each rhythm classification. Efficacy as a function of time after therapy was also deter-
mined.
Results: 293 episodes from 34 patients were included in the analysis. All patients were
ICD indicated with a history of = 1 atrial arrhythmia in the 12 months preceding implant.
Average age was 70±10 years, the majority of patients were NHYA class II with an aver-
age LVEF of 34±14%. 147 episodes (50%) were classified as SVT, 121 (41%) as DSVT
and 25 (9%)as Afib. Atrial ATP efficacy was determined at several times post-therapy and
found to improve significantly as a function of time, with 21% conversion at 10 secs (post
therapy stored EGM) increasing to 41% at 40 secs (device defined efficacy), 47% at 1
min and 57.8% at 3 min. Efficacy was significantly dependent on rhythm type (33% effi-
cacy for SVTs, 12% for DSVTs and 0% for Afib) and rate (overall efficacy for rhythms of <
200bpm was 69% versus 39% for >200bpm).
Conclusion: We conclude that atrial ATP has significant therapeutic potential for some
types of AT. Additional analysis is required to determine any positive correlation between
programming scheme and ATP efficacy.
1091-226 Implantable Cardioverter Defibrillator Follow-Up: Will 
Office Visits Be Replaced by Transtelephonic 
Monitoring?
Andrea M. Russo, Hemal Nayak, Henry Hsia, David Lin, Ralph Verdino, Jamie Scotti, 
Lisa Ahlemeyer, Francis E. Marchlinski, University of Pennsylvania Health System, 
Philadelphia, PA
Background: Outpatient implantable cardioverter defibrillator (ICD) follow-up (FU) is
routinely performed every 3 to 4 months, at which time device interrogation and repro-
gramming are possible. Transtelephonic monitoring (TTM) is currently available for of
ICDs, which initially includes device interrogation without reprogramming. It is unclear
whether or not TTM will replace in-office FU. Methods: We reviewed outpatient charts on
78 patients (pts) with 587 office visits (median 7) to determine the frequency of interven-
tions performed at FU. Reprogramming of tachycardia and bradycardia parameters, and
changes in medical regimens based on ICD interrogations, were examined. Results:
Mean age was 65 ± 12 yrs and ejection fraction 32 ± 16%. Presentation included sus-
tained VT/VF in 20 pts, syncope 27 pts, and no symptoms 31 pts. Based on ICD interro-
gations, tachycardia (VT/VF) detection changes were made in 27 pts (35%), bradycardia
changes 48 pts (62%), miscellaneous changes 16 pts (21%), and antiarrhythmic drug
changes 17 pts (22%). Tachycardia changes included reprogramming VT or VF rate cut-
off in 18 pts, turning on VT zone 12 pts, programming detection enhancements 13 pts,
and increasing shock energy 3 pts. Bradycardia changes included decreasing lower rate
in 14 pts, increasing pacing output 20 pts, decreasing pacing output 30 pts, changing rate
response 7 pts, and changing mode 4 pts. Miscellaneous changes included reprogram-
ming magnet function in 3 pts, turning device back "on" 2 pts, reprogramming capacitor
maintenance 9 pts, and using new software 4 pts. Changes were made due to VT/VF
detections with device therapy or aborted shocks in 13 pts, SVT detections 19 pts, arti-
fact 2 pts, bradycardia 10 pts, paced rate too fast 9 pts, increased pacing threshold 20
